Sarcopenia and mortality in older hemodialysis patients

(1) Sarcopenia is a progressive loss of skeletal muscle mass and strength. The aim of this study was to determine the association of sarcopenia, defined according to the Working Group on Sarcopenia in Older People (EWGSOP2) diagnostic criteria, with mortality at 24 months in very elderly hemodialysi...

Descripción completa

Detalles Bibliográficos
Autores: Sánchez-Tocino, M. Luz, Miranda Serrano, Blanca, López González, Antonio, Villoria González, Silvia, Gracia-Iguacel, Carolina, González-Ibarguren, Isabel, Ortíz-Arduan, Alberto, Mas-Fontao, Sebastian, González-Parra, Emilio
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universidad de Salamanca (USAL)
Repositorio:GREDOS. Repositorio Institucional de la Universidad de Salamanca
OAI Identifier:oai:gredos.usal.es:10366/154333
Acceso en línea:http://hdl.handle.net/10366/154333
Access Level:acceso abierto
Palabra clave:Sarcopenia
EWGSOP2
Elderly
Hemodialysis
Kidney replacement therapy
Mortality
Kidney failure
Prospective Studies
Renal Dialysis
Prevalence
prevalencia
sarcopenia
estudios prospectivos
diálisis renal
id ES_d782bda17d1d3d15607ebdb0daffe7e2
oai_identifier_str oai:gredos.usal.es:10366/154333
network_acronym_str ES
network_name_str España
repository_id_str
spelling Sarcopenia and mortality in older hemodialysis patientsSánchez-Tocino, M. LuzMiranda Serrano, BlancaLópez González, AntonioVilloria González, SilviaGracia-Iguacel, CarolinaGonzález-Ibarguren, IsabelOrtíz-Arduan, AlbertoMas-Fontao, SebastianGonzález-Parra, EmilioSarcopeniaEWGSOP2ElderlyHemodialysisKidney replacement therapyMortalityKidney failureProspective StudiesSarcopeniaRenal DialysisPrevalenceprevalenciasarcopeniaestudios prospectivosdiálisis renal(1) Sarcopenia is a progressive loss of skeletal muscle mass and strength. The aim of this study was to determine the association of sarcopenia, defined according to the Working Group on Sarcopenia in Older People (EWGSOP2) diagnostic criteria, with mortality at 24 months in very elderly hemodialysis patients. (2) A prospective study was conducted in 60 patients on chronic hemodialysis who were older than 75 years. Sarcopenia was diagnosed according to EWGSOP2 criteria. Additionally, clinical, anthropometric and analytical variables and body composition by bioimpedance were assessed. The date and cause of death were recorded during 2 years of follow-up. (3) Among study participants, 41 (68%) were men, the mean age 81.85 ± 5.58 years and the dialysis vintage was 49.88 ± 40.29 months. The prevalence of probable sarcopenia was 75% to 97%, depending on the criteria employed: confirmed sarcopenia ranged from 37 to 40%, and severe sarcopenia ranged from 18 to 37%. A total of 30 (50%) patients died over 24 months. Sarcopenia probability variables were not related to mortality. In contrast, sarcopenia confirmation (appendicular skeletal muscle mass, ASM) and severity (gait speed, GS) variables were associated with mortality. In multivariate analysis, the hazard ratio (95% confidence interval) for all-cause death was 3.03 (1.14-8.08, p = 0.028) for patients fulfilling ASM sarcopenia criteria and 3.29 (1.04-10.39, p = 0.042) for patients fulfilling GS sarcopenia criteria. (4) The diagnosis of sarcopenia by EWGSOP2 criteria is associated with an increased risk of all-cause death in elderly dialysis patients. Specifically, ASM and GS criteria could be used as mortality risk markers in elderly hemodialysis patients. Future studies should address whether the early diagnosis and treatment of sarcopenia improve outcomes.This research received no external funding. E.G.-P., S.M.-F. and A.O.-A. research groups are funded by Ministerio de Economia, Industria y competitividad: FIS/Fondos FEDER (PI16/01298, PI17/00257, PI18/01386, PI19/00588, PI19/00815, PI20/00487, PI21/01430, ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, ISCIII-RETIC REDinREN RD016/0009) and Sociedad Española de Nefrología, Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM. All authors want to thank Fundación Renal Íñigo Álvarez de Toledo (FRIAT) for its support to renal research in Spain. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Financiadores Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM FRIAT Fundación Renal Íñigo Álvarez de Toledo Ministerio de Economia Sociedad Española de Nefrología Spain Federación Española de Enfermedades Raras Spain PI21/01430202420242022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10366/154333reponame:GREDOS. Repositorio Institucional de la Universidad de Salamancainstname:Universidad de Salamanca (USAL)InglésAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:gredos.usal.es:10366/1543332026-06-07T06:28:51Z
dc.title.none.fl_str_mv Sarcopenia and mortality in older hemodialysis patients
title Sarcopenia and mortality in older hemodialysis patients
spellingShingle Sarcopenia and mortality in older hemodialysis patients
Sánchez-Tocino, M. Luz
Sarcopenia
EWGSOP2
Elderly
Hemodialysis
Kidney replacement therapy
Mortality
Kidney failure
Prospective Studies
Sarcopenia
Renal Dialysis
Prevalence
prevalencia
sarcopenia
estudios prospectivos
diálisis renal
title_short Sarcopenia and mortality in older hemodialysis patients
title_full Sarcopenia and mortality in older hemodialysis patients
title_fullStr Sarcopenia and mortality in older hemodialysis patients
title_full_unstemmed Sarcopenia and mortality in older hemodialysis patients
title_sort Sarcopenia and mortality in older hemodialysis patients
dc.creator.none.fl_str_mv Sánchez-Tocino, M. Luz
Miranda Serrano, Blanca
López González, Antonio
Villoria González, Silvia
Gracia-Iguacel, Carolina
González-Ibarguren, Isabel
Ortíz-Arduan, Alberto
Mas-Fontao, Sebastian
González-Parra, Emilio
author Sánchez-Tocino, M. Luz
author_facet Sánchez-Tocino, M. Luz
Miranda Serrano, Blanca
López González, Antonio
Villoria González, Silvia
Gracia-Iguacel, Carolina
González-Ibarguren, Isabel
Ortíz-Arduan, Alberto
Mas-Fontao, Sebastian
González-Parra, Emilio
author_role author
author2 Miranda Serrano, Blanca
López González, Antonio
Villoria González, Silvia
Gracia-Iguacel, Carolina
González-Ibarguren, Isabel
Ortíz-Arduan, Alberto
Mas-Fontao, Sebastian
González-Parra, Emilio
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Sarcopenia
EWGSOP2
Elderly
Hemodialysis
Kidney replacement therapy
Mortality
Kidney failure
Prospective Studies
Sarcopenia
Renal Dialysis
Prevalence
prevalencia
sarcopenia
estudios prospectivos
diálisis renal
topic Sarcopenia
EWGSOP2
Elderly
Hemodialysis
Kidney replacement therapy
Mortality
Kidney failure
Prospective Studies
Sarcopenia
Renal Dialysis
Prevalence
prevalencia
sarcopenia
estudios prospectivos
diálisis renal
description (1) Sarcopenia is a progressive loss of skeletal muscle mass and strength. The aim of this study was to determine the association of sarcopenia, defined according to the Working Group on Sarcopenia in Older People (EWGSOP2) diagnostic criteria, with mortality at 24 months in very elderly hemodialysis patients. (2) A prospective study was conducted in 60 patients on chronic hemodialysis who were older than 75 years. Sarcopenia was diagnosed according to EWGSOP2 criteria. Additionally, clinical, anthropometric and analytical variables and body composition by bioimpedance were assessed. The date and cause of death were recorded during 2 years of follow-up. (3) Among study participants, 41 (68%) were men, the mean age 81.85 ± 5.58 years and the dialysis vintage was 49.88 ± 40.29 months. The prevalence of probable sarcopenia was 75% to 97%, depending on the criteria employed: confirmed sarcopenia ranged from 37 to 40%, and severe sarcopenia ranged from 18 to 37%. A total of 30 (50%) patients died over 24 months. Sarcopenia probability variables were not related to mortality. In contrast, sarcopenia confirmation (appendicular skeletal muscle mass, ASM) and severity (gait speed, GS) variables were associated with mortality. In multivariate analysis, the hazard ratio (95% confidence interval) for all-cause death was 3.03 (1.14-8.08, p = 0.028) for patients fulfilling ASM sarcopenia criteria and 3.29 (1.04-10.39, p = 0.042) for patients fulfilling GS sarcopenia criteria. (4) The diagnosis of sarcopenia by EWGSOP2 criteria is associated with an increased risk of all-cause death in elderly dialysis patients. Specifically, ASM and GS criteria could be used as mortality risk markers in elderly hemodialysis patients. Future studies should address whether the early diagnosis and treatment of sarcopenia improve outcomes.
publishDate 2022
dc.date.none.fl_str_mv 2022
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10366/154333
url http://hdl.handle.net/10366/154333
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:GREDOS. Repositorio Institucional de la Universidad de Salamanca
instname:Universidad de Salamanca (USAL)
instname_str Universidad de Salamanca (USAL)
reponame_str GREDOS. Repositorio Institucional de la Universidad de Salamanca
collection GREDOS. Repositorio Institucional de la Universidad de Salamanca
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421010789335040
score 15,300719

Similares en LA Referencia